

Seattle Genova

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

BioActive Human ARID1A oncogenic mutation Recombinant Protein,Fc Tag

Catalog Number:SGRP00657

DESCRIPTION	
Product Name	BioActive Human ARID1A oncogenic mutation Recombinant Protein,Fo
Gene Name	ARID1A
Source	Full length Human AREG amplification, expressed in HEK293 cells.
Alternative names	
SPECIFICATIONS	
Biological Activity	Fully biologically active
Purity	> 95% by SDS-PAGE & HPLC
Endotoxin Level	< 1.0 EU per μg protein as determined by the LAL method
Expression System	HEK293 Cells
Format	Recombinant
Species	Human
Predicted MW	
Actual MW	
Applications	Sandwich ELISA Functional Studies Mass Spectrometry SDS-PAGE HPL
Form	Lyophilized from sterile PBS, pH 7.40
Concentration	N/A
Stability and Storage	Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	Reconstitute with Phosphate Buffered Saline.
BACKGROUND	
Gene Accession	O14497
Gene Alias	Protein names Recommended name AT-rich interactive domain-containing protein 1A Short names ARID domain-containing protein 1A Alternative names B120 BRG1-associated factor 250 (BAF250) BRG1-associated factor 250a (BAF250A) Osa homolog 1 (hOSA1) SWI-like protein Gene names Name ARID1A Synonyms BAF250, BAF250A, C1orf4, OSA1, SMARCF1



Seattle Genova

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

can be lost after initiation. ARID1A mutations are present in 10% of colorectal cancers and, similar to GC, are thought to be caused by mismatch defects.

Background

ARID1A, a SWI/SNF chromatin remodeling gene, is commonly mutated in cancer and hypothesized to be tumor suppressive. In some hepatocellular carcinoma patients, ARID1A was highly expressed in primary tumors but not in metastatic lesions, suggesting that ARID1A